NASDAQ: ERAS

⬣ Investigation

healthcare

Erasca, Inc.

Securities Investigation

Stock dropped 9.95% on October 16, 2026

Investors who purchased or acquired ERAS securities are encouraged to come forward.

Investigation in Progress — No Complaint Filed Yet

BG&G is actively investigating potential securities fraud claims against Erasca, Inc.. If a complaint is filed, this page will be updated. Investors are encouraged to contact us now to preserve their rights.

Why Is Erasca, Inc. (ERAS) Under Investigation?

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of shareholders of Erasca, Inc. (NASDAQ: ERAS).

On October 16, 2026, Erasca disclosed in a filing with the U.S. Securities and Exchange Commission that “the employment of Nicholas (Nik) Chetwyn, Ph.D., the Company’s Chief Operating Officer, will terminate effective November 2, 2026.” Erasca attributed the termination to the Company’s decision “to realign its leadership responsibilities to support the development and potential commercialization of its RAS-targeting programs.” Following this news, Erasca’s stock price fell $1.48 per share, or 9.95%, to close at $13.39 per share on October 16, 2026.

What Potential Securities Violations Is BG&G Investigating?

  • Whether Erasca, Inc. and certain of its officers made false or misleading statements regarding the Company's financial condition and business prospects.
  • Whether Erasca, Inc. failed to disclose material adverse information that would have been significant to a reasonable investor.
  • Whether the Company's earnings guidance was supported by a reasonable factual basis at the time it was made.

What Should Erasca, Inc. (ERAS) Investors Do?

If you purchased or acquired ERAS securities and suffered a loss, you may have a claim.
Contact BG&G to share relevant facts or information about your purchase.
There is no cost or obligation — our firm works exclusively on a contingency fee basis.
You do not need to have sold your shares to contact us.

How Is Erasca, Inc. (NASDAQ: ERAS) Stock Trading Today?

How Does BG&G Help Investors in Securities Fraud Investigations?

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

We handle cases on a contingency fee basis — we advance all litigation costs on your behalf. There is no fee unless we are successful.

“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace.”
— Peretz Bronstein, Founding Partner